Related Experiment Video
Updated: Jan 29, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Homocysteine, Thioretinaco Ozonide, and Oxidative Phosphorylation in Cancer and Aging: A Proposed Clinical Trial
1Department of Pathology, Harvard Medical School, Boston, MA, USA. kilmer.mccully@va.gov.
Abstract:
The objective of the proposed clinical interventional trial is to demonstrate the efficacy of a novel therapeutic strategy in subjects with cancer and hyperhomocysteinemia. Following discovery of abnormal homocysteine thiolactone metabolism in cultured malignant cells, thioretinamide, the amide synthesized from retinoic acid and homocysteine thiolactone, and thioretinaco, the complex formed from cobalamin and thioretinamide, were demonstrated to have antineoplastic, anticarcinogenic, and anti-atherogenic properties in animal models. Retinol, ascorbate, and homocysteine thiolactone are necessary for biosynthesis of thioretinamide and thioretinaco by cystathionine synthase and for formation of thioretinaco ozonide from thioretinamide, cobalamin, and ozone. Thioretinaco ozonide is required for prevention of abnormal oxidative metabolism, aerobic glycolysis, suppressed immunity, and hyperhomocysteinemia in cancer.The pancreatic enzyme therapy of cancer promotes catabolism of proteins, nucleic acids, and glycosaminoglycans with excess homocysteinylated amino groups resulting from abnormal accumulation of homocysteine thiolactone in malignant cells. Dietary deficiencies of pyridoxal, folate, cobalamin, and nitriloside contribute to hyperhomocysteinemia in cancer, and in protein energy malnutrition. A deficiency of dietary sulfur amino acids downregulates cystathionine synthase, causing hyperhomocysteinemia.The organic sulfur compound diallyl trisulfide increases hydrogen sulfide production from homocysteine in animal models, inhibits Stat3 signaling in cancer stem cells, and produces apoptosis of malignant cells. The furanonaphthoquinone compound napabucasin inhibits Stat3 signaling and causes mitochondrial dysfunction, decreased oxidative phosphorylation, and apoptosis of malignant cells. The protocol of the proposed clinical trial in subjects with myelodysplasia consists of thioretinamide and cobalamin as precursors of thioretinaco ozonide, combined with pancreatic enzyme extracts, diallyl trisulfide, napabucasin, nutritional modification to minimize processed foods, vitamin supplements, essential amino acids, and beneficial dietary fats and proteins.
Insights
This study investigates a novel cancer therapy combining thioretinamide and cobalamin to form thioretinaco ozonide, addressing hyperhomocysteinemia and promoting apoptosis in cancer patients.
Area of Science:
- Oncology
- Biochemistry
- Metabolic Medicine
Background:
- Abnormal homocysteine thiolactone metabolism is observed in malignant cells.
- Thioretinamide and thioretinaco exhibit antineoplastic and anticarcinogenic properties in preclinical models.
- Hyperhomocysteinemia in cancer is linked to dietary deficiencies and altered sulfur amino acid metabolism.
Purpose of the Study:
- To evaluate the efficacy of a novel therapeutic strategy for cancer and hyperhomocysteinemia.
- To investigate the role of thioretinaco ozonide in preventing cancer-associated metabolic dysfunction.
- To explore combination therapy including novel compounds and nutritional modifications.
Main Methods:
- Proposed clinical trial for myelodysplasia subjects.
- Utilizing thioretinamide and cobalamin as precursors for thioretinaco ozonide synthesis.
- Administering pancreatic enzyme extracts, diallyl trisulfide, and napabucasin.
- Implementing nutritional modifications, vitamin supplements, and essential amino acids.
Main Results:
- Thioretinamide and thioretinaco demonstrate antineoplastic, anticarcinogenic, and anti-atherogenic effects in animal models.
- Thioretinaco ozonide is crucial for preventing abnormal oxidative metabolism, aerobic glycolysis, and immune suppression in cancer.
- Diallyl trisulfide and napabucasin inhibit cancer stem cell signaling and induce apoptosis.
Conclusions:
- The proposed combination therapy targets key metabolic pathways and signaling in cancer.
- This strategy aims to reverse hyperhomocysteinemia and enhance anti-cancer immune responses.
- Further clinical investigation is warranted to validate efficacy in myelodysplasia and other cancers.
More Related Videos
07:13Platelet-based Detection of Nitric Oxide in Blood by Measuring VASP Phosphorylation
Published on: January 7, 2019
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Statistical Software for Data Analysis and Clinical Trials
Oxidation Numbers
Trial and Error and Algorithm